14.37 USD
-0.20
1.37%
Updated Feb 12, 12:13 PM EST
1 day
-1.37%
5 days
-5.15%
1 month
-4.45%
3 months
-8.99%
6 months
71.07%
Year to date
5.82%
1 year
-39.14%
5 years
-48.68%
10 years
-48.68%
 

About: CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

Employees: 200

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

163% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 8

119% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 16

100% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 2 (+1) [Q3]

54% more call options, than puts

Call options by funds: $653K | Put options by funds: $425K

16% more funds holding

Funds holding: 73 [Q2] → 85 (+12) [Q3]

2.86% more ownership

Funds ownership: 61.99% [Q2] → 64.85% (+2.86%) [Q3]

23% less capital invested

Capital invested by funds: $161M [Q2] → $124M (-$36.4M) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$20
39%
upside
Avg. target
$22
51%
upside
High target
$23
60%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
Matt O'Brien
62% 1-year accuracy
32 / 52 met price target
39%upside
$20
Overweight
Maintained
5 Feb 2025
Canaccord Genuity
William Plovanic
74% 1-year accuracy
35 / 47 met price target
60%upside
$23
Buy
Maintained
5 Feb 2025
Craig-Hallum
Alexander Nowak
60% 1-year accuracy
9 / 15 met price target
53%upside
$22
Buy
Maintained
17 Jan 2025

Financial journalist opinion

Based on 7 articles about CVRX published over the past 30 days

Neutral
Zacks Investment Research
1 day ago
CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
CVRx (CVRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Positive
Zacks Investment Research
5 days ago
Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in CVRx (CVRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know
Neutral
Seeking Alpha
1 week ago
CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript
CVRx, Inc. (NASDAQ:CVRX ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandler Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the CVRx Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript
Negative
Zacks Investment Research
1 week ago
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.44 per share a year ago.
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 week ago
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024.
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
Neutral
GlobeNewsWire
3 weeks ago
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
Positive
Zacks Investment Research
3 weeks ago
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?
CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?
Neutral
GlobeNewsWire
1 month ago
CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The Company is scheduled to present at 2:15 PM Pacific Time the same day via webcast.
CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Neutral
GlobeNewsWire
2 months ago
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024. The Company is scheduled to present at 3:30 PM Eastern Time the same day via webcast.
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
Positive
Seeking Alpha
3 months ago
CVRx: Impressive Top-Line Growth Seems Priced In
CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution.
CVRx: Impressive Top-Line Growth Seems Priced In
Charts implemented using Lightweight Charts™